Takeda's exclusive distribution of Pfizer products in Japan

TakedaTakeda Pharmaceutical Company Limited ("Takeda") and Pfizer Japan Inc. ("Pfizer") announced that they have concluded an agreement that, as of December 31, 2012, Takeda will cease distribution of 13 out of the 15 Pfizer products that it previously procured from Wyeth K.K. and currently distributes under an exclusive distribution agreement with Pfizer, and that Pfizer, the manufacturer of the products, will begin selling them thereafter. In addition, Takeda will continue to distribute the pneumococcus vaccine Prevenar® for infants and young children and hemophilia B drug BeneFIX® (generic name: nonacog alfa) after January 2013.

Aside from this exclusive distribution agreement, the two companies agreed in February 2011 to extend the term of co-promotion agreement of the rheumatoid arthritis (RA) drug Enbrel® (generic name: etanercept), the marketing of which Takeda will continue.

Takeda and Pfizer will remain committed to the prevention and treatment of diseases by providing drugs that meet the needs of patients and medical professionals through their successful partnership.

About Takeda Pharmaceutical Company Limited
Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for patients worldwide through leading innovation in medicine.

About Pfizer
Pfizer, a world's leading research-based pharmaceutical, is focusing on research, development and manufacturing of medicines for people and animals. We strive to support people's lifelong health and well-being and contribute to improving quality of life through innovative and valuable products globally.

Most Popular Now

Bayer Thrombosis Research Award 2019 goes to Dr. C…

The fourth winner of the Bayer Thrombosis Research Award has been chosen. The Scientific Committee of the Bayer Science & Education Foundation awarded the EUR 30,000 priz...

Roche enters into definitive merger agreement to a…

Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) have entered into a definitive merger agreement for Roche to fully acquire Spark Therapeuti...

Brilinta’s Phase III THEMIS trial met primary endp…

The Phase III THEMIS trial met its primary endpoint and demonstrated that Brilinta (ticagrelor), taken in conjunction with aspirin, showed a statistically-significant red...

Protein content as a marker for response to therap…

Brain tumors vary widely in how they respond to treatment. However, early assessment of therapy response is essential in order to choose the best possible treatment for t...

Jury upholds Amgen's patents on Repatha® (evolocum…

Amgen (NASDAQ:AMGN) announced that a Delaware jury delivered a verdict in Amgen's favor upholding the validity of two Amgen patents related to PCSK9 antibodies. These pat...

Artificial lung cancer tissue could help find new …

A 3D hydrogel created by researchers in U of T Engineering Professor Molly Shoichet's lab is helping University of Ottawa researchers to quickly screen hundreds of potent...

Could medical marijuana help grandma and grandpa w…

Medical marijuana may bring relief to older people who have symptoms like pain, sleep disorders or anxiety due to chronic conditions including amyotrophic lateral scleros...

New treatment offers potentially promising results…

A pioneering clinical trials program that delivered an experimental treatment directly to the brain offers hope that it may be possible to restore the cells damaged in Pa...

Amgen, Cytokinetics and Servier announce start of …

Amgen (NASDAQ: AMGN), Cytokinetics, Incorporated (NASDAQ: CYTK) and Servier today announced that METEORIC-HF (Multicenter Exercise Tolerance Evaluation of Omecamtiv Mecar...

Could blockchain ensure integrity of clinical tria…

UC San Francisco researchers have created a proof-of-concept method for ensuring the integrity of clinical trials data with blockchain. The system creates an immutable au...

Novartis data confirm rapid response and high effi…

Novartis announced today new data in 441 Chinese patients with moderate to severe plaque psoriasis from a Phase III study investigating the efficacy and safety of Cosenty...

Abbott and Novo Nordisk enter partnership to provi…

Abbott and Novo Nordisk today announced a non-exclusive partnership that will integrate insulin dose data from Novo Nordisk pre-filled and durable connected pens directly...